The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).
 
Philippe Alexandre Cassier
Honoraria - Amgen
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Janssen Oncology; OSE Immunotherapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
 
Christophe Alfons Dooms
No Relationships to Disclose
 
Anas Gazzah
No Relationships to Disclose
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS
 
Neeltje Steeghs
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Ellipses Pharma (Inst); Luzsana Biotechnology (Inst)
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); Ascendis Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); Cantargia AB (Inst); CellCentric (Inst); Cogent Biosciences (Inst); Crescendo Biologics (Inst); Cytovation (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); InteRNA (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Kling Biotherapeutics (Inst); Lilly (Inst); Luzsana Biotechnology (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Molecular Partners (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kristoffer Staal Rohrberg
Honoraria - Amgen; Bayer; MSD; MSD
Research Funding - Alligator Bioscience (Inst); AstraZeneca (Inst); Bayer (Inst); Bioinvent (Inst); Black Diamond Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genmab (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Merus (Inst); MonTa Biosciences (Inst); Novartis (Inst); Orion Clinical (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rain Therapeutics (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Symphogen (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Bristol-Myers Squibb; Roche
 
Filippo G. De Braud
Honoraria - Amgen Astellas BioPharma; BMS; Incyte; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD SERONO; Incyte; Menarini; Nerviano Medical Sciences; Nerviano Medical Sciences; Novartis Italy; Pierre Fabre; Roche; Sanofi
Research Funding - Basilea Pharmaceutical; Bayer Health; Bristol-Myers Squibb/Medarex; Daiichi Sankyo Europe GmbH; Exelixis; Ignyta; incyte; Janssen Oncology; Kymab (Inst); Loxo (Inst); MedImmune; Merck KGaA; Merck Serono (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Benjamin J. Solomon
Honoraria - Amgen (Inst); AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; GlaxoSmithKline (Inst); Janssen; Lilly; Merck Sharp & Dohme; Novartis (Inst); Pfizer (Inst); Roche/Genentech; Takeda
Research Funding - Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Martin H. Schuler
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck Serono; Novartis; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; C4 Therapeutics; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Ono Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Herbert H. F. Loong
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Eisai; GlaxoSmithKline; Guardant Health; Illumina; Lilly; Novartis; Roche/Genentech; Takeda
Speakers' Bureau - Bayer; Guardant Health; Ignyta; Novartis
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; CJ bioscience; CureLogen; Cyrus therapeutics; GI Cell; Guardant Health; Hanmi; Imnewrun; inno.N; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Onegene Biotechnology; Ono Pharmaceutical; Oscotec; Pfizer; RandBio; Roche; Takeda; Yuhan
Research Funding - Abbvie; Abion; AstraZeneca; Bayer; Blueprint medicines; Boehringer Ingelheim; Bridgebio; CHA Bundang Medical Center; Champions Oncology; CJ bioscience; CJ Blossom Park; Cyrus Therapeutics; Dizal Pharma; Dong-A ST; Genexine; GI Cell; GI Innovation; Hanmi; Illumina; ImmuneOncia; Interpark Bio; J Ints Bio; Janssen; Kanaph therapeutics; LG Chem; Lilly; Mogam Biotechnology Research Institue; MSD; Novartis; Nuvalent, Inc.; Oncternal Therapeutics; Ono Pharmaceutical; Oscotec; Regeneron; Therapex; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen
Other Relationship - DAAN Biotherapeutics
 
Juergen Wolf
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen; Lilly; Loxo; Loxo/Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo/Lilly; Merck; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Janssen; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Abbvie; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; IMPAC Medical Systems; Novartis; PharmaEngine
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; IMPAC Medical Systems; Lilly
 
Marcelo Vailati Negrao
Consulting or Advisory Role - Genentech; Merck; Mirati Therapeutics; Novartis
Research Funding - Alaunos Therapeutics (Inst); AstraZeneca (Inst); Checkmate Pharmaceuticals (Inst); Genentech (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
Other Relationship - Apothecom; Ashfield Healthcare; ZIOPHARM Oncology
 
Lillian Werner
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Xiaoming Cui
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Anna F. Farago
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Consulting or Advisory Role - AstraZeneca; Bayer
 
Maria J. de Miguel
No Relationships to Disclose